** Brokerage TD Cowen starts coverage on drug developer Lenz Therapeutics LENZ.O with "buy" rating and $60 PT, as it expects "high consumer satisfaction" with co's once-daily eye drop, LNZ100
** Says LNZ100 has demonstrated "best-in-class efficacy and clean safety" in treating presbyopia, a condition that affects 128 mln US adults, causing an inability to focus on near objects
** Estimates over $1 bln in peak sales for LNZ100, representing just "2% of presbyopia market"
** Says unlike competitor AbbVie's ABBV.N Vuity which has "poor tolerability/safety, with short duration of effect," LNZ100's aceclidine is "derisked for real-world safety"
** Brokerage says investors should "buy the derisked commercial story, as the launch should impress" and potentially "surprise to the upside"
** The US drug regulator is expected to decide on approval for LNZ100 in early August
** LENZ gained 131% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.